Fresh analysis indicates that people who discontinue popular slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional lifestyle plans.
Research printed in a prominent medical journal points out that while overweight individuals frequently drop about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these drugs should be aware of the risk of rapid weight regain when the medication concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery implies a return to original weight within about one and a half years.
Comparing Treatments
The research, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of these new drugs with other pills.
Scientists point out that people who shed pounds through lifestyle changes alone generally experience a slower creep back—approximately 100 grams monthly—once they finish.
Explaining the Fast Rebound
Nutrition scientists propose the mode of action of the jabs accounts for the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Artificially providing the hormone concentrations several times higher than normal could lead to the system to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
The NHS advise the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the high risk of weight regain, the treatment is often long-term.
This perspective is supported by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," similar to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the jabs describe a intense resurgence of hunger.
"I experienced something that goes on and I was suddenly ravenous," described one woman.
The struggle is compounded if users have not adopted permanent lifestyle or habit changes during therapy.
Significant Use
Survey data suggest that a significant number of people in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while the jabs are potent agents for weight loss, they are not a permanent solution and long-term success relies on combined behavioural support.
